RxDoctor Payments Data

Lenore Brancato, MD

Rheumatology · Roslyn, NYNPI 1154367886

Payments from drug & device makers

$677in general payments, 2019–2025

Across 34 payments — averaging $19.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$179
  • GSK$152
  • Johnson & Johnson$137
  • AbbVie$110
  • Pfizer$44
  • Pacira Therapeutics, Inc.$19
  • plus $36 from 2 others

What the payments were for

  • Food & beverage$66298%
  • Education$152%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)12$179
GSK6$152
Johnson & Johnson8$137
AbbVie3$110
Pfizer2$44
Pacira Therapeutics, Inc.1$19
AstraZeneca1$19
Lilly USA, LLC1$17

How this compares

$677 in reported general payments places this provider in the 35th percentile of 541 rheumatology providers in New York.

See all rheumatology providers in New York

Medicare billing

Part B allowed, 2024
$47,515
Medicare patients
194
Services billed
766

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast11$87,666
RinvoqUpadacitinib12$73,163
Teriparatide14$43,683
Diclofenac Sodium51$29,666
LinzessLinaclotide13$6,917
RasuvoMethotrexate/Pf12$6,318
Hydroxychloroquine Sulfate120$3,192
Risedronate Sodium DrRisedronate Sodium15$2,548
Cevimeline Hcl18$2,376
Duloxetine Hcl109$2,302
Colchicine25$2,099
Risedronate Sodium44$1,824
Celecoxib68$996
Raloxifene Hcl21$882
Lidocaine12$775

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$179$87,66611 claims
AbbVieRinvoq, Linzess$110$80,08025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 541 rheumatology providers in New York.

Other rheumatology in Roslyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →